AstraZeneca : Vaccin COVID-19 : de bons résultats mais pas les meilleurs
>AstraZeneca satisfait de l’efficacité préliminaire de son vaccin - AZN a publié hier juste avant l’ouverture des marchés les premières données de phase 3 pour son vaccin COVID-19. Sur près de 12 000 volontaires dont 131 ont contracté la maladie 14 jours après la deuxième injection, le vaccin AZD1222 a permis une réduction moyenne de 70% du risque de développer une maladie symptomatique par rapport au placebo. Néanmoins cette efficacité diffère selon le dosage du vacc...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.